Results 211 to 220 of about 14,491 (226)

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial

Cancer Science, 2020
Reiji Fukano, Ryuta Asada, Kengo Takeuchi   +2 more
exaly  

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Lancet, The, 2017
Toyoaki Hida, Takashi Seto, Yuichi Takiguchi   +2 more
exaly  

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Lancet Oncology, The, 2016
Gregory J Riely, Bo H Chao, Kathryn A Gold   +2 more
exaly  

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Lancet Respiratory Medicine,the, 2019
Sang-We Kim, Thanyanan Ruengwetwattana, Jianying Zhou   +2 more
exaly  

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer

Nature Ecology and Evolution, 2019
Artem Kaznatcheev, Jeffrey Peacock, David Basanta   +2 more
exaly  

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

Acta Pharmaceutica Sinica B, 2015
Zilan Song, Ao Zhang
exaly  

First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced ALK-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.

Value in Health
R. Mudumba, Jorge J. Nieva, W. Padula
semanticscholar   +1 more source

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo

Experimental and Molecular Medicine, 2017
Kenneth Kin Wah To, De-Lan Li, Likun Chen   +2 more
exaly  

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib

Journal of Thoracic Oncology, 2016
Shiro Fujita, Yasushi Yatabe
exaly  

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells

Neoplasia, 2016
Shaomeng Wang
exaly